The UK and US have signed a significant trade agreement that will ensure zero duties on British medicine products entering the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment secures that tariffs on these key goods will remain at zero for a period of three years.
This deal is in response to recent threats to dramatically increase tariffs on patented pharmaceutical products, with potential rates mentioned up to double the cost.
"This arrangement between the UK bolsters the international landscape for cutting-edge drugs and introduces long-overdue balance to American-British medicine commerce," a statement said.
Trade Importance
Medicines constitute one of the UK's biggest goods shipped to the US, which is clearly the biggest destination for leading UK drugmakers.
Export figures reveal that in the 12 months leading up to the third quarter, the UK shipped drugs worth £11.1bn to the US. This figure represented 17.4% of total UK exports in that period.
"This deal safeguards jobs, stimulates funding and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister remarked.
Specific NHS Changes
The pact entails several key commitments from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates topped twenty percent.
Industry Background
The pact takes place against a long-running dispute between the sector and the ministers over medicine costs and approval rates.
This friction were intensified by assertions that American patients were charged a premium for the same drugs than people in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been paused or cancelled, while major investments have been directed toward US facilities.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the past decade.
